- Previous Close
121.50 - Open
121.10 - Bid --
- Ask --
- Day's Range
120.40 - 121.60 - 52 Week Range
99.70 - 126.70 - Volume
8,800 - Avg. Volume
65,182 - Market Cap (intraday)
10.008B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
15.22 - EPS (TTM)
7.95 - Earnings Date Feb 13, 2025
- Forward Dividend & Yield 1.20 (0.99%)
- Ex-Dividend Date May 30, 2024
- 1y Target Est
128.13
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
www.ipsen.com5,325
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: IPN.PA
View MorePerformance Overview: IPN.PA
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPN.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPN.PA
View MoreValuation Measures
Market Cap
10.05B
Enterprise Value
9.83B
Trailing P/E
15.28
Forward P/E
11.83
PEG Ratio (5yr expected)
3.97
Price/Sales (ttm)
2.96
Price/Book (mrq)
2.63
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
9.92
Financial Highlights
Profitability and Income Statement
Profit Margin
19.83%
Return on Assets (ttm)
8.48%
Return on Equity (ttm)
17.91%
Revenue (ttm)
3.44B
Net Income Avi to Common (ttm)
663.9M
Diluted EPS (ttm)
7.95
Balance Sheet and Cash Flow
Total Cash (mrq)
485.4M
Total Debt/Equity (mrq)
12.11%
Levered Free Cash Flow (ttm)
523.86M